JAK2V617F Mutation in Patients with Portal Vein Thrombosis

Bayraktar, Yusuf; Harmancı, Özgür; Büyükaşık, Yahya; Shorbagi, Ali; Sungur, Aysegul Hasegeli; Boylu, Cemaliye Akyerli; Gürgey, Aytemiz; Balkancı, Ferhun

doi:10.1007/s10620-008-0225-y

Cited by 26 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-four studies were therefore included in this systematic review. 10,21,23,25,27,30,33,37,[40][41][42][43][44][45][46][47][48][49]51,52 Interobserver agreement for study selection was excellent ( ϭ 0.96).…”

Section: Study Identification and Selectionmentioning

confidence: 99%

“…Studies ranged in size from 11 to 560 patients; a total of 3508 patients were included. Six case-control studies 10,23,25,27,35,40 and 18 retrospective cohort studies 21,24,30,31,34,36,37,[41][42][43][44][45][46][47][48][49]51,52 were included in our systematic review. Five studies enrolled patients consecutively.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…35,42,44,46,51 A few studies differentiated between patients with homozygote and heterozygote JAK2V617F mutation, 24,34,35,41,43,44,49 and 2 studies provided data on patients with homozygote mutation JAK2V617F. [24][25][26][27][28][29][30][31][32][33][34][35] Sixteen studies, 10,21,[23][24][25]30,[35][36][37]40,43,44,46,47,49,53 including a total 831 patients, assessed the prevalence of JAK2V617F mutation in patients with SVT. Eight studies, 21,27,34,37,[40][41][42]47 …”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis

Dentali

Squizzato

Brivio

et al. 2009

Blood

161

136

View full text Add to dashboard Cite

Recent studies suggested that JAK2V617F mutation is frequent in patients with splanchnic vein thrombosis (SVT) but not in patients with other venous thromboembolic events (VTE). However, whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Therefore, we performed a systematic review to assess the frequency of JAK2 mutation in VTE patients and the role of JAK2V617F mutation in the diagnosis of myeloproliferative neoplasms. MEDLINE and EMBASE databases were searched. Two reviewers independently performed study selection and extracted study characteristics. Pooled odds ratios of case-control studies and weighted mean proportion of the prevalence of JAK2V617F mutation of uncontrolled series were calculated. Twenty-four studies involving 3123 patients were included. Mean prevalence of JAK2 mutation was 32.7% (95% confidence interval, 25.5%-35.9%) in SVT patients. JAK2 mutation was associated with increased risk of SVT (odds ratio, 53.98; 95% confidence interval, 13.10-222.45). Mean prevalence of JAK2 mutation in other VTE patients was low (range, 0.88%-2.57%). Presence of JAK2V617F mutation in SVT patients was associated with a subsequent diagnosis of myeloproliferative neoplasm in many patients. JAK2 mutation is strongly associated with SVT, and routine screening of JAK2 mutation appears to be indicated in these patients. (Blood. 2009;113:5617-5623)

show abstract

Section: Study Identification and Selectionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis

Dentali

Squizzato

Brivio

et al. 2009

Blood

161

136

View full text Add to dashboard Cite

show abstract

“…Several studies have focused on the prevalence of JAK2 V617F mutation in patients with venous thrombosis. In patients with splanchnic vein thrombosis and without overt MPN, JAK2 V617F positivity has ranged from 12 to 74% [7,8,9,10,11,12,13,14,15,16] with a mean prevalence of 32.7% [17]. This wide range of JAK2 mutation positivity could be explained by several factors, including heterogeneity in the inclusion criteria, small sample size, different sensitivities of the assays employed for the detection of the mutation, and the different types of biological samples used [18].…”

Section: Introductionmentioning

confidence: 99%

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

Lamy¹,

Palazzo

Agius³

et al. 2017

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: The presence of Janus Kinase 2 (JAK2) V617F mutation represents a major diagnostic criterion for detecting myeloproliferative neoplasms (MPN) and even in the absence of overt MPN, JAK2 V617F mutation is associated with splanchnic vein thrombosis. However, the actual prevalence and diagnostic value of the JAK2 V617F mutation in patients with cerebral venous thrombosis (CVT) are not known. The aims of this study were to assess the prevalence of JAK2 V617F mutation in a large group of consecutive CVT patients, to detect clinical, biological, and radiological features associated with the mutation, and to determine the long-term venous thrombosis recurrence rate in CVT patients with JAK2 mutation but without overt MPN in order to recommend the best preventive treatment. Methods: This was a prospective study conducted on consecutive patients with a first-ever radiologically confirmed CVT. JAK2 V617F mutation analysis was assessed in all the study subjects. JAK2 V617F-positive patients were followed up to detect new venous thrombotic events. Results: Of the 125 included subjects, 7 were found to have JAK2 V617F mutation (5.6%; 95% CI 2.3-11.2). Older age (p = 0.039) and higher platelet count (p = 0.004) were independently associated with JAK2 V617F positivity in patients without overt MPN. During a mean follow-up period of 59 (SD 46) months, 2 JAK2 V617F-positive patients presented with 4 new venous thromboembolic events. Conclusions: Screening for the JAK2 V617F mutation in CVT patients seems to be useful even in the absence of overt MPN and/or in the presence of other risk factors for CVT because of its relatively high prevalence and the risk of thrombosis recurrence.

show abstract

“…It has been reported that JAK2 (V617F) mutation is present in 50-79.3 % all cases of diagnosed MPN with SVT. On the other hand, in patients with latent MPN with SVT, the incidence of JAK2 (V617F) mutation varies from 11 to 74 % [13][14][15][16][17][18][19][20][21][22][23]. Only one retrospective study reported a low prevalence rate of 9.3 % [24].…”

Section: Jak2 (V617f) Mutation Myeloproliferative Neoplasms and Splementioning

confidence: 99%

JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis

Salhotra

2012

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

JAK2V617F Mutation in Patients with Portal Vein Thrombosis

Cited by 26 publications

References 29 publications

JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis

JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis

Contact Info

Product

Resources

About